Biotech startup’s latest partnership gets its UniPen into the hands of more pharmacists

A new strategic partnership for Love Lifesciences is expected to leverage its core product — a safe, self-administered injection medication delivery system — to new groups of like-minded, innovation-first companies, said Nick Love.

The Overland Park biotech startup on Wednesday announced the deal with the Alliance for Pharmacy Compounding (APC), a leading trade organization, to advance patient care by promoting Love Lifesciences’ flagship UniPen device to APC’s more than 200 member pharmacies.

UniPen is a versatile safety injection device designed for a wide range of self-administered injectable therapies, including such popular treatments as GLP-1 agonists, testosterone, and other injectables commonly produced by compounding pharmacies.

Love Lifesciences will provide APC member pharmacies access to UniPen at industry-best pricing, said Love, CEO and co-founder of the company alongside Bradley Hopper.

“APC’s support for UniPen and Love Lifesciences further signifies the direction that the compounding pharmacy industry is moving forward with by integrating new innovations to target improvements to patient care,” he added. “The partnership demonstrates the levels of interest and desire from the compounding pharmacy industry as a whole, not just from APC alone.”

Click here to learn more about UniPen and its uses for patients, biotech and pharma.

Because the UniPen’s delivery system is therapeutically agnostic — meaning it can solve for a spectrum of treatment needs — its value proposition is strong among compounding pharmacies, said Love.

“Without UniPen’s ability to be applied to a wide range of injectable products, pharmacies would be unable to leverage UniPen in a variety of therapeutic lines which would limit the products’ application,” he explained. “With the therapeutic agnostic nature, these pharmacies can select which therapeutic lines they want to integrate UniPen into such as Testosterone, GLP-1s, Hormone Replacement Therapies, or even injectable blood thinners, all without device redevelopment timelines or costs.”

“This can be extended beyond different therapeutic lines and can even be applied to and accommodate various dosing requirements individual patients may have,” Love added. “In doing so, the pharmacies can achieve a multi-fold effect of obtaining a significant competitive advantage in each of these therapeutic markets while also providing their patients an improved injection experience or even a more customized injectable product to meet their specific needs.”

With its focus on patient safety and ease of use, UniPen provides pre-set medication dosing and anti-needlestick features, which adds to its value, he noted

“UniPen was designed to improve the patient injection experience,” said Love. “In doing so, we’re not only targeting improved adherence, and patient outcomes therein, but also empowering these patients to take control over their own health. Our relationship with APC underscores the importance that APC and their compounding pharmacy members place on patient centricity. We are very excited to be a part of this movement.” 

One of Startland News’ 10 Kansas City Startups to Watch in 2024, Love Lifesciences this month earned a regional Business Innovation award from the Kansas Department of Commerce at the state agency’s Oct. 3 “To The Stars: Kansas Business Awards” ceremony.

“Our state has been reaching unprecedented heights in terms of business investment and economic growth in Kansas thanks to companies such as those we’re honoring here,” said Lt. Gov. David Toland, D-Kansas, who also serves as secretary of commerce. “Each of the nominees play a critical role in the new era of Kansas we are creating — they are truly the pillars of our success and more than worthy of being celebrated.”

Click here to read more about the Kansas-owned businesses recognized at the event.

The post Biotech startup’s latest partnership gets its UniPen into the hands of more pharmacists appeared first on Startland News.